Gabelli & Co Investment Advisers’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-148,400	Closed	-$3.58M	–	320
2023 Q1	$3.58M	Buy	+148,400	New	+$1.86M	0.69%	38

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Gabelli & Co Investment Advisers's PRVB Position: Q2 2023 in Review

Gabelli & Co Investment Advisers sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 148,400 shares — an estimated $3.58M sold.

Gabelli & Co Investment Advisers first reported a position in PRVB in Q1 2023 and held it in 1 quarter. The position peaked at $3.58M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Gabelli & Co Investment Advisers reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 148,400 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $3.58M.
Gabelli & Co Investment Advisers first reported a position in Provention Bio, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Gabelli & Co Investment Advisers's Provention Bio, Inc. Common Stock position peaked at $3.58M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.